Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications
Beteiligte:
Barbagallo, Federica;
Campolo, Federica;
Franceschini, Edoardo;
Crecca, Elena;
Pofi, Riccardo;
Isidori, Andrea M.;
Venneri, Mary Anna
Erschienen:
MDPI AG, 2020
Erschienen in:
Endocrines, 1 (2020) 2, Seite 90-101
Sprache:
Englisch
DOI:
10.3390/endocrines1020009
ISSN:
2673-396X
Entstehung:
Anmerkungen:
Beschreibung:
Pharmacological inhibition of Phosphodiesterase type 5 (PDE5) proved its efficacy treating several pathological conditions, such as erectile dysfunction and pulmonary hypertension. Nowadays, its benefits on cardiovascular diseases are well documented, particularly in the treatment of type 2 diabetes (T2DM)-related cardiovascular complications. In this context, treatment of T2DM with PDE5 inhibitors, such as sildenafil, tadalafil or vardenafil ameliorates endothelial dysfunction both in patients and animal models through an augmented flow mediated dilation rate and an up-regulation of endothelial markers; it also reduces the inflammatory state by down-regulating inflammatory cytokines expression and improves diabetic cardiomyopathy and ischemia-reperfusion injury mainly through the activation of NO-cGMP-PKG pathway. The present review summarizes the state of art on PDE5 inhibition in the treatment of cardiovascular complications in T2DM.